Breast cancer claims approximately 670,000 lives annually. World Health Organisation (WHO) data from 2022 show that breast cancer is the most prevalent cancer among women in 157 out of 185 countries. Over two million women are diagnosed with breast cancer each year, highlighting the importance of early detection and targeted treatment. The US Food and Drug Administration (FDA) has approved Kisqali, also known as ribociclib, for early-stage breast cancer treatment. This drug can be used in combination with hormone therapy for patients concerned about cancer recurrence. Kisqali works as a selective cyclin-dependent kinase inhibitor, targeting proteins that promote cancer cell growth. Administered orally, Kisqali is prescribed for three-week cycles with a one-week break, to be continued for three years. It can be taken with or without food at a recommended daily dose of 400 mg.Kisqali: Side effects

Common side effects of Kisqali medication include low white blood cell count, also known as neutropenia, which reduces the levels of neutrophils in the blood. Neutrophils play a crucial role in battling infections in the body. Additionally, Kisqali may lead to liver problems and interstitial lung disease or pneumonitis.

Breast Cancer: Important early signs that should not be overlooked